Regardless of the 4 day rule, they can delay the completion and finalization of TLD results for quite some time. SEC suggested guidelines are stated as 12 to 15 months as being timely.
My feelings about this trial is that overall all it failed, except for a certain subgroup. But this trial represents a unique moment in medical history. As a historic discovery so profound that the scientist involved were awarded a Nobel Prize for their research on October 19, 2019. This discovery will be the pivotal game changer in immuno theapies in my opinion. How Dendritic cells have a duel functions (hif2a on off switch VDL gene site) was only a hypothesis when the dVax trial was started. We are in a situation where bad news can actually be good news. Science is a process that is compromised of research & development. Breaking the word research down to having the ability to go back to a precise point and look again. It's my analysis that NWBO is delaying the release of TLD until the release of Merck's first in class small molecule potent Hif2a inhibitor MK 6482 Belzutifan.
In the situation regarding my friends cancer, I thought that I scored big when I hooked her up with the news of the gloves off Dana Farber (Harvard) $15million ovarian cancer study. After contacting the doctor involved, who is considered to be the worlds best. She was very enthusiastic that she could help her. Their team is eagerly awaiting the first production batch of Merck's Belzutifan. She informed her to continue with her current doctor and start round 5 with your doctor's decision. She expressly informed her to not start any immuno therapies.
A gain in my opinion this trial and NWBO stock price will not be a Hero or Zero scenario. Even with end point failure NWBO will be a prime buy-out candidate. My prediction Merck buyout DVax,Keytruda combined with Belzutifan and world historic event will result.
